SARS-CoV-2 variant booster vaccination and infection alter the breadth of the memory B cell repertoire
Authors:
- Rory MalekRMRory Malek
- Flavio MatassoliFMFlavio Matassoli
- Geoffrey D. ShimbergGSGeoffrey D. Shimberg
- Grace E. MantusGMGrace E. Mantus
- Abby SpanglerASAbby Spangler
- Ankita J. ChopdeACAnkita J. Chopde
- I-Ting TengITI-Ting Teng
- Tongqing ZhouTZTongqing Zhou
- Bob C. LinBLBob C. Lin
- Rachel KazmierskiRKRachel Kazmierski
- 10 June 2026
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (853) , eaeb9847
Abstract
Evolving endemic viruses such as influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain major health threats. Although variant updated vaccines aim to enhance protection, preexisting immunity shapes memory B cell (MBC) responses. To assess how SARS-CoV-2 spike protein variant–based vaccine boosters and infections alter the MBC repertoire, we analyzed MBC responses in the COVAIL vaccine trial, where participants previously vaccinated with SARS-CoV-2 Wuhan-1 spike immunogen were boosted with Wuhan-1, variant, or bivalent spike immunogens. Some participants also experienced a subsequent infection with an Omicron variant. We determined that variant vaccine boosters and SARS-CoV-2 infections led to transiently greater recall of cross-reactive MBCs compared with a Wuhan-1 vaccine booster. Long term, we detected little change in the MBC repertoire after an Omicron vaccine booster, but MBCs evaluated several months after Omicron variant infection had higher neutralization capacity to both Wuhan-1 and BA.1 compared with those from individuals who had not experienced an infection. However, these Wuhan-1/BA.1 cross-reactive MBCs from infected individuals displayed less breadth toward the more distant BA.2.86 lineage than MBCs from uninfected individuals. Thus, SARS-CoV-2 variant boosters and infections differentially shape the long-term MBC repertoire.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (HHSN261200800001E)
- National Institute of Allergy and Infectious Diseases (75N910D00024)
- National Institute of Allergy and Infectious Diseases (75N93021C00012)
- National Institute of Allergy and Infectious Diseases (UM1AI148684)
- National Institute of Allergy and Infectious Diseases
- Biomedical Advanced Research and Development Authority (75A50122C00008)
- Biomedical Advanced Research and Development Authority (75N93021D00021)
- Biomedical Advanced Research and Development Authority (W15QKN-16-9-1002)
This publication has 49 references indexed in Scilit:
- Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic driftCell Reports, 2025
- A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike proteinCell Reports, 2025
- Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variantsEBioMedicine, 2024
- Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responsesCell Reports, 2024
- Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1Cell Reports, 2024
- Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescentsCell Reports, 2022
- LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsCell Reports, 2022
- Structural and molecular basis for foot-and-mouth disease virus neutralization by two potent protective antibodiesProtein & Cell, 2021
- Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular ProbesCell Reports, 2020
- Immune history and influenza virus susceptibilityCurrent Opinion in Virology, 2017